VORONOI Inc.

11:00 AM - 11:15 AM, Thursday, June 6,2019 ・ Theater 1
VORONOI primarily develops small molecule inhibitors of kinases using kinase profiling and molecular modeling. Major TAs are oncology, CNS, and auto-immune diseases. VORONOI's business focuses on discovery, pre-clinical, and early stage clinical trials, and therefore, partnering with pharmas capable for late stage clinical trials and marketing/sales is key to success for our lead compounds showing promising efficacy data. We not only develop compounds on our own, but also license in promising compounds from global research institutes and universities including Dana Farber Cancer Institute (DFCI). We are targeting to begin 3-4 clinical trials in 2019, and one is soon to be started (IND filing submited). We have 8-9 compounds under pre-clinical development and plan to add more compounds to our pipeline in 2019
Speaker
photo
Head of BD
VORONOI Inc.